Sangamo BioSciences (SGMO) PT Raised to $30 at Barclays
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Sangamo BioSciences (SGMO) PT Raised to $33 at Jefferies
February 23, 2018 8:58 AM ESTJefferies raised its price target on Sangamo BioSciences (NASDAQ: SGMO) to $33.00 (from $18.00) while maintaining a Buy rating.
... MoreSangamo BioSciences (SGMO) PT Raised to $35 at JPMorgan
February 23, 2018 7:24 AM ESTJPMorgan raised its price target on Sangamo BioSciences (NASDAQ: SGMO) to $35.00 (from $11.00) while maintaining a Overweight rating.
... MoreSangamo BioSciences (SGMO) PT Raised to $32 at Piper Jaffray, Remains Positive Citing Broadening Platform
February 22, 2018 4:26 PM ESTPiper Jaffray raised its price target on Sangamo BioSciences (NASDAQ: SGMO) to $32.00 (from $25.00) while maintaining a Overweight rating.
... MoreSangamo BioSciences (SGMO) PT Raised to $39 at Wells Fargo
February 22, 2018 12:23 PM ESTWells Fargo raised its price target on Sangamo BioSciences (NASDAQ: SGMO) to $39.00 (from $30.00) while maintaining a Outperform rating.
The analyst likes the company's competitive advantage in gene-editing, which is attributed to years of experience with single loci targeting and suspects it should be... More
Sangamo Therapeutics (SGMO) Tops Q4 EPS by 3c
February 22, 2018 7:22 AM ESTSangamo Therapeutics (NASDAQ: SGMO) reported Q4 EPS of ($0.15), $0.03 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $13.1 million versus the consensus estimate of $11.43 million.
For earnings history and earnings-related data on Sangamo Therapeutics (SGMO) click here.
... More